Can a diabetes drug boost weight loss after bypass surgery?
NCT ID NCT06162715
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This pilot trial tests whether tirzepatide, a drug used for diabetes and weight loss, can help people who still have obesity one year after gastric bypass surgery. Thirty participants will either receive the drug or standard care. The study tracks weight changes and any stomach-related side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tirzepatide (also known as Zepbound or Mounjaro)
- What this could lead to
- If it works, this could offer a new option for people who still have obesity after gastric bypass surgery, helping them lose more weight.
- What could go wrong
- This is a small pilot study with only 30 people, so results may not apply to everyone. Side effects like gastrointestinal symptoms are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BMI GREATER THAN 30 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37209, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?